A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 May 2018

At a glance

  • Drugs Sunitinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 May 2018 Results of a secondary analysis assessing the impact of baseline characteristics on the outcomes of sorafenib-treated advanced HCC patients (n=544) published in the Journal of Cancer Research and Clinical Oncology
    • 23 Jun 2012 Company added in the association field as reported by EudraCT.
    • 21 Apr 2012 Additional trial locations (Czech Republic, Hungary, Portugal) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top